Literature DB >> 24931918

Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance.

D van Duin1, E D Cober, S S Richter, F Perez, M Cline, K S Kaye, R C Kalayjian, R A Salata, S R Evans, V G Fowler, R A Bonomo.   

Abstract

Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an increasing global threat. Here, we describe the prevalence and impact of tigecycline use in a cohort of patients with CRKP bacteriuria nested within a multicentre, prospective study. In the 21-month study period, 260 unique patients were included. Tigecycline was given to 80 (31%) patients. The use of tigecycline during the index hospitalization was significantly associated with the subsequent development of tigecycline resistance in the same patient (OR, 6.13; 95% CI, 1.15-48.65; p 0.03). In conclusion, the use of tigecycline with CRKP bacteriuria is common, and is associated with the subsequent development of tigecycline resistance.
© 2014 The Authors Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  Carbapenem-resistant Enterobacteriaceae; multidrug resistance; urinary tract infection

Mesh：

Substances：

Year:  2014        PMID： 24931918      PMCID： PMC4265572          DOI： 10.1111/1469-0691.12714

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


  9 in total

1.  CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.

Authors:  Teresa C Horan; Mary Andrus; Margaret A Dudeck
Journal:  Am J Infect Control       Date:  2008-06       Impact factor: 2.918

2.  Nested case-control study of the emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae.

Authors:  Masayuki Nigo; Catalina Salinas Cevallos; Krystina Woods; Vicente Maco Flores; Gweneth Francis; David C Perlman; Manuel Revuelta; Donna Mildvan; Mary Waldron; Tessa Gomez; Sanjana Koshy; Tomasz Jodlowski; William Riley; Jörg J Ruhe
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

3.  Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates.

Authors:  Laure Diancourt; Virginie Passet; Jan Verhoef; Patrick A D Grimont; Sylvain Brisse
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

Review 4.  Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes.

Authors:  David van Duin; Keith S Kaye; Elizabeth A Neuner; Robert A Bonomo
Journal:  Diagn Microbiol Infect Dis       Date:  2013-01-03       Impact factor: 2.803

5.  Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network.

Authors:  David van Duin; Federico Perez; Susan D Rudin; Eric Cober; Jennifer Hanrahan; Julie Ziegler; Raymond Webber; Jacqueline Fox; Pamela Mason; Sandra S Richter; Marianne Cline; Geraldine S Hall; Keith S Kaye; Michael R Jacobs; Robert C Kalayjian; Robert A Salata; Julia A Segre; Sean Conlan; Scott Evans; Vance G Fowler; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

6.  Genomic analysis of the emergence and evolution of multidrug resistance during a Klebsiella pneumoniae outbreak including carbapenem and colistin resistance.

Authors:  Elena López-Camacho; Rosa Gómez-Gil; Raquel Tobes; Marina Manrique; María Lorenzo; Beatriz Galván; Estefanía Salvarelli; Youssef Moatassim; Iñigo J Salanueva; Eduardo Pareja; Francisco M Codoñer; Miguel Alvarez-Tejado; María Pilar Garcillán-Barcia; Fernando De la Cruz; Jesús Mingorance
Journal:  J Antimicrob Chemother       Date:  2013-10-23       Impact factor: 5.790

Review 7.  Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary.

Authors:  J W Chow; V L Yu
Journal:  Int J Antimicrob Agents       Date:  1999-01       Impact factor: 5.283

8.  Trends in resistance to carbapenems and third-generation cephalosporins among clinical isolates of Klebsiella pneumoniae in the United States, 1999-2010.

Authors:  Nikolay P Braykov; Michael R Eber; Eili Y Klein; Daniel J Morgan; Ramanan Laxminarayan
Journal:  Infect Control Hosp Epidemiol       Date:  2013-01-23       Impact factor: 3.254

9.  In vitro susceptibility of multidrug-resistant Enterobacteriaceae clinical isolates to tigecycline.

Authors:  Te-Din Huang; Catherine Berhin; P Bogaerts; Y Glupczynski
Journal:  J Antimicrob Chemother       Date:  2012-07-24       Impact factor: 5.790
  9 in total
  36 in total

1.  Tigecycline resistance among Klebsiella pneumoniae isolated from febrile neutropenic patients.

Authors:  Sherein G Elgendy; Muhammad R Abdel Hameed; Mohamed A El-Mokhtar
Journal:  J Med Microbiol       Date:  2018-05-25       Impact factor: 2.472

2.  Carbapenem-resistant Enterobacteriaceae: What we know and what we need to know.

Authors:  David van Duin
Journal:  Virulence       Date:  2017-04-12       Impact factor: 5.882

3.  Residence in Skilled Nursing Facilities Is Associated with Tigecycline Nonsusceptibility in Carbapenem-Resistant Klebsiella pneumoniae.

Authors:  David van Duin; Eric Cober; Sandra S Richter; Federico Perez; Robert C Kalayjian; Robert A Salata; Scott Evans; Vance G Fowler; Robert A Bonomo; Keith S Kaye
Journal:  Infect Control Hosp Epidemiol       Date:  2015-05-20       Impact factor: 3.254

Review 4.  The global epidemiology of carbapenemase-producing Enterobacteriaceae.

Authors:  David van Duin; Yohei Doi
Journal:  Virulence       Date:  2016-08-11       Impact factor: 5.882

5.  Decreased Susceptibility to Tigecycline Mediated by a Mutation in mlaA in Escherichia coli Strains.

Authors:  Fang He; Juan Xu; Jianfeng Wang; Qiong Chen; Xiaoting Hua; Ying Fu; Yunsong Yu
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 6.  Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.

Authors:  Elizabeth A Neuner; Jason C Gallagher
Journal:  Virulence       Date:  2016-08-09       Impact factor: 5.882

7.  Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae.

Authors:  David van Duin; Eric Cober; Sandra S Richter; Federico Perez; Robert C Kalayjian; Robert A Salata; Scott Evans; Vance G Fowler; Keith S Kaye; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2014-12-09       Impact factor: 5.790

8.  Risk Factors, Outcomes, and Mechanisms of Tigecycline-Nonsusceptible Klebsiella pneumoniae Bacteremia.

Authors:  Chih-Han Juan; Yi-Wei Huang; Yi-Tsung Lin; Tsuey-Ching Yang; Fu-Der Wang
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

9.  Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality.

Authors:  Laura J Rojas; Madiha Salim; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Steve Marshall; Susan D Rudin; T Nicholas Domitrovic; Andrea M Hujer; Kristine M Hujer; Yohei Doi; Keith S Kaye; Scott Evans; Vance G Fowler; Robert A Bonomo; David van Duin
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

Review 10.  Carbapenemase-producing Enterobacteriaceae.

Authors:  Yohei Doi; David L Paterson
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.